Halozyme Therapeutics HALO Quick ratio
Quick ratio at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's quick ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Halozyme Therapeutics's quick ratio?
- Halozyme Therapeutics (HALO) reported quick ratio of 2.7× in Q1 2026.
- How has Halozyme Therapeutics's quick ratio changed year-over-year?
- Halozyme Therapeutics's quick ratio decreased by 66.7% year-over-year, from 8.2× to 2.7×.
- What is the long-term trend for Halozyme Therapeutics's quick ratio?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's quick ratio has grown at a 31.1% compound annual growth rate (CAGR), from 1.2× to 4.5×.
- What does quick ratio mean?
- Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.